AMASS Botanics

AMASS Botanics

Growth Stage

Portfolio of premium, high-growth botanic beverages and self care products

Portfolio of premium, high-growth botanic beverages and self care products


Raised this Round:
$1,441,223 - RegCF
$5,132,879 - Total

Total Commitments ($USD)



Start Date


Close Date


Min. Goal
Max. Goal
Min. Investment


Security Type

Equity - Preferred



SEC Filing Type

RegCF / RegD 506(c)    Open SEC Filing

Price Per Share


Pre-Money Valuation


Year Founded



Fitness & Wellness

Tech Sector


Distribution Model




Capital Intensity



LOS ANGELES, California

Business Type


AMASS Botanics, with a valuation of $75 million, is raising funds on SeedInvest. It is a botanical body care and spirits brand that makes clean botanics suiting the modern lifestyle. The self-care portfolio contains hand sanitizer, hand soap, bath salts, and lotion, while the beverage portfolio consists of botanic gin and vodka, botanic non-alcoholic spirit, cannabis spirit, and Aperitivo. AMASS Botanics has an $8 million revenue run rate as of the fourth quarter of 2020. The business reported a 549% year-over-year growth in revenue from 2019 to 2020. Mark Thomas Lynn founded AMASS Botanics in 2016. The current crowdfunding campaign has a minimum target of $25,000 and a maximum target of $5,000,000. The campaign proceeds will be used for new products, marketing, and team expansion.

Summary Profit and Loss Statement

Most Recent Year Prior Year












Net Income



Summary Balance Sheet

Most Recent Year Prior Year




Accounts Receivable



Total Assets



Short-Term Debt



Long-Term Debt



Total Liabilities



Financials as of: 09/11/2021
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
AMASS Botanics 01/27/2022 SeedInvest $75,000,000 $5,132,879 Equity - Preferred Funded RegCF / RegD 506(c)
AMASS Botanics 09/10/2021 SeedInvest $75,000,000 $3,361,732 Equity - Preferred Funded Test the Waters
Create a free account today to gain access to KingsCrowd analytics.

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Valuation History

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)


$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.

Ratings KingsCrowd Startup Rating Methodology Article

Blurred Ratings Bars Blurred Ratings Bars

Analyst Report Analyst Report Methodology Article


There’s a change happening in the alcohol industry. Beer sales have declined steadily in recent years, while the markets for other varieties of alcohol have expanded. Hard seltzer is the buzzy trend, of course. Sales were up 66% year-over-year in 2019, though they’ve recently slowed. Ready-to-drink cocktails became the star of increased alcohol demand during the COVID-19 pandemic. While traditional spirits like vodka and gin aren’t new alcohol options, they are growing in popularity. The spirits market grew by 3% each year between 2006 and 2016. Consumers are experimenting with new types of alcoholic beverages (and even cannabidiol-infused beverages and no-alcohol cocktail lookalikes), and many new brands are cashing in. 

AMASS Botanics hopes to be one of them. The company produces a large portfolio of alcoholic beverages, including plant-infused vodka, dry gin, hard seltzers, cannabis-infused spirits, and no-alcohol spirits. The company also leverages its natural, botanics-forward brand to market self-care products like hand sanitizer, soap, and lotion. With more than $3.4 million in revenue in 2020, AMASS is growing quickly to stake out a spot in the liquor and self-care aisles. 

AMASS Botanics’ current SeedInvest raise has been rated a Neutral Deal by the KingsCrowd investment team. 

Next Section: Price


AMASS Botanics is offering preferred equity at a $75 million pre-money valuation. This price is much too high for the company’s current stage. With only $3.4 million in revenue, a $75 million pre-money valuation represents a 22x revenue-to-valuation multiple. That’s far too large for an early-stage consumer packaged goods company in a highly competitive market. At this valuation, AMASS will have to scale dramatically to deliver a strong return for investors. There’s little evidence to suggest that AMASS has what it takes to become a billion-dollar company, so investors aren’t facing excellent odds.

Next Section: Market


AMASS Botanics has a somewhat scattered product portfolio that touches several segments of the alcohol market and also the market for personal care products. AMASS is introducing alcoholic products in segments with growing demand. The global market for premium spirits was valued at $107.74 billion in 2019 and is expected to grow at an impressive 10.3% annual growth over the next six years. Another good sign for AMASS is that the spirits market is growing more fragmented over time, and demand is increasing for premium spirits brands faster than for non-premium alternatives. AMASS’ hard seltzer products also meet a growing market that’s valued at $4.4 billion in 2019 and is projected to grow 16.2% yearly over the next six years. 

For AMASS Botanics’ personal care line (hand sanitizers, soaps, lotions, etc.), market demand is large and steady. The full US beauty and personal care products market is projected to hit $128.7 billion by 2030. The market specifically for natural personal care products is expected to grow at a healthy 9.3% annual rate over the next seven years.

AMASS Botanics has a wide line of products, and all of them reside in large and growing markets. AMASS’ lack of focus on one market and the stiff competitiveness of each of these markets raise concerns, but the company benefits from pure market demand and growth potential.

Next Section: Team


AMASS Botanics was co-founded by Mark Thomas Lynn and Morgan McLachlan. CEO Lynn is the company’s business brain. He has impressive experience as the co-founder of several successful startups. His first company,, was acquired by LeagueApps in 2008. Since then, Lynn co-founded Winc Wines (a DTC wine company with more than $250 million in lifetime revenue) and Digital Brands Group, a NASDAQ-listed collection of digital-first luxury brands. 

Chief Product Officer Morgan McLachlan also serves as AMASS’ lead distiller. McLachlan founded The Spirit Guild in Los Angeles 10 years ago and has been honing her craft ever since. Her spirits have won several awards. 

The AMASS Botanics team includes several other executives, including Chief Revenue Officer Gene Song and Chief Digital Officer Jennifer Fan. Song previously served as the vice president of crafted spirits for Rémy Cointreau, a leading spirits brand. He has more than two decades of cumulative business experience, 15 of which are in the liquor industry. Jennifer Fan most recently led customer retention at REVOLVE, a millennial-focused e-commerce clothing boutique. Both Song and Fan hold bachelor’s degrees and MBAs from Ivy League schools. 

All in all, the AMASS Botanics team is well developed. It includes senior executives from highly relevant companies, including Winc Wines and Rémy Cointreau. The senior leadership team has decades of combined business experience with several former exits and advanced degrees. It’s difficult to imagine a team more qualified to lead a growing alcohol startup. 

Next Section: Differentiators


Differentiation is often where consumer packaged goods companies fall flat, particularly in the alcohol industry. Each brand claims that its value proposition is unique. But the alcohol aisle is crowded with emerging brands focused on natural ingredients, fewer calories, millennial branding, sophisticated taste, and more. Most marketing messages get lost in the clutter, and AMASS Botanics is no different. While premium spirits and seltzers distilled with plants may have seemed more unique two decades ago, there are now several options that meet the same criteria. Haus is a prime example of a competitor touting similar messaging as AMASS — alcohol for the modern drinker, focused on clean and natural ingredients. 

AMASS Botanics argues on its raise page that its focus on self-care products like hand sanitizers and soaps are a differentiator from most alcohol brands. It’s true that this approach is unique, but it’s not at all clear why the strategy actually benefits AMASS. Hard seltzer and lotion isn’t an obvious product combination, and it doesn’t seem like a competitive advantage. The company’s claims that this product diversity allows for better data insights and customer targeting aren’t backed by evidence. 

Given the stiff competition of the alcohol industry and the personal care industry), it’s very difficult for AMASS to have strong differentiation. Furthermore, defensibility is often an issue with consumer packaged goods, and AMASS suffers here as well. The company has little to set it apart from competitors. 

Next Section: Performance


AMASS Botanics is showing several signs of success. For one, the company’s revenue growth is impressive, particularly given the COVID-19 pandemic. In 2019, AMASS brought in $534,617 in revenue. In 2020, revenue jumped to more than $3.4 million, representing 540% year-over-year revenue growth. That’s a major surge for a young direct-to-consumer brand. However, AMASS’ net loss also grew between 2019 and 2020 from $2.56 million to $3.35 million. 

All of this revenue growth is thanks to steady progress in securing distribution accounts around the world. AMASS Botanics is sold in more than 1,500 stores and restaurants around the US, with additional distribution in the UK, Spain, Netherlands, Greece, Singapore, and Hungary. Five Michelin-starred restaurants serve AMASS Botanics products. The company’s direct-to-consumer channel is reportedly also growing steadily, though precise metrics aren’t offered. 

In addition, AMASS Botanics has been unusually successful in raising money, likely due to its CEO’s strong network as an exited entrepreneur. AMASS has raised $11 million across five prior rounds, from a $2 million valuation cap all the way to this round’s $75 million pre-money valuation. All of this fundraising has diluted the founders’ ownership significantly, down to 23.65%, which is unusual for a startup at this stage and may cause less founder buy-in than investors would prefer. 

The data is clear. AMASS Botanics has grown steadily over the last two years, with a strong distribution network and enthusiastic backing from previous investors. If this trajectory continues, AMASS will continue to scale toward potential returns for investors.

Next Section: Risks


An investment in AMASS Botanics offers a low-to-moderate risk profile. The riskiest factor prospective investors should consider is the company’s financial status. The company’s roughly 1.5 debt-to-asset ratio is very weak and indicates that investors risk losing their money if AMASS were to go bankrupt in the near future. Beyond financials, prospective investors should consider more moderate risks in the areas of time, funding, and market. Direct-to-consumer brands typically scale more slowly than high-growth software businesses and may require more funding to fuel growth. Further inhibiting that growth is a highly competitive market. There’s no guarantee that increased time or funding can actually push AMASS Botanics past the other brands vying for market share. However, the company has exhibited strong year-over-year revenue growth and is an increasingly well-established alcohol brand with international distribution. 

Next Section: Bearish Outlook

Bearish Outlook

The alcohol market is extremely competitive. It’s too soon to say whether AMASS Botanics actually has any sort of secret sauce to outpace the huge number of emerging brands vying for market share. The company insists that its personal care product line is a differentiator, but that’s not a clear argument. There’s no obvious reason why selling hand sanitizer and lotion creates any sort of proprietary data pipeline that enables more efficient alcohol sales. In fact, one could argue that focusing on both alcohol sales and personal care product sales actually holds AMASS back from being truly successful in either domain. 

Lack of focus seems to be an issue. Even within the alcohol product line, AMASS simultaneously offers premium spirits and hard seltzer, and it will soon introduce no-alcohol spirits and cannabis-infused spirits. Most startups focus on just one of these segments as it takes significant effort to carve out market share from longtime liquor giants. Given the pressure that AMASS Botanics faces to scale quickly and justify this round’s inflated valuation, prospective investors have reason to be concerned that the company is doing too much at once. 

Next Section: Bullish Outlook

Bullish Outlook

AMASS Botanics is a bit of a confusing brand, given its focus on both alcohol and personal care products. At first glance, it may seem as though the company is still struggling to hone in on its lane. However, AMASS’ performance data tells a different story. With more than 500% year-over-year revenue growth between 2019 and 2020, almost $4 million in lifetime revenue, and significant distribution infrastructure around the globe, AMASS seems to have found a formula that’s working. 

AMASS’ success isn’t entirely surprising, considering the strength of its team. The company’s CEO is a seasoned entrepreneur with multiple exits, including prior experience as the co-founder of a successful direct-to-consumer alcohol brand. Other executives previously occupied senior roles at growing startups and established alcohol businesses, with decades of combined experience and strong academic credentials. 

All of these are strong signals that AMASS might have what it takes to scale into an attractive acquisition opportunity for a larger alcohol brand. Acquisitions are common in this industry. There are numerous examples of well-branded startups that catch the eye of liquor giants like Anheuser-Busch or smaller spirits brands that are building a portfolio of product offerings. Given AMASS’ steady growth and its CEO’s industry connections, investors could potentially achieve returns with a lucrative exit in coming years.

Next Section: Executive Summary

Executive Summary

AMASS Botanics is primarily an alcohol brand selling premium botanics-infused spirits, hard seltzers, and more. The company also produces a line of personal care products, like hand sanitizers and soaps. In just a few years of operation, AMASS Botanics has scaled internationally to more than 1,500 stores and restaurants and generated almost $4 million in revenue. The company is led by an experienced founding team with domain expertise in the alcohol industry. 

On the other hand, AMASS Botanics seems to be splitting focus between alcohol and personal care, a strategy with little obvious upside. Its debt-to-asset ratio is weak, and prospective investors should also be concerned that a $75 million pre-money valuation is inflated for a consumer packaged goods startup of this size. Therefore, AMASS Botanics has been rated a Neutral Deal. 

For questions regarding the KingsCrowd staff pick or ratings for this company, please reach out to

Analysis written October 4, 2021. 

Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
AMASS Botanics on SeedInvest 2021
Platform: SeedInvest
Security Type: Equity - Preferred
Valuation: $75,000,000
Price per Share: $3.80

Follow company

Follow AMASS Botanics on SeedInvest 2021

Buy AMASS Botanics's Deal Report

Warning: according to the close date for this deal, AMASS Botanics may no longer be accepting investments.

AMASS Botanics Deal Report

Get KingsCrowd’s comprehensive report on AMASS Botanics including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether AMASS Botanics is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise
  • Our deep-dive analyst report reviewing the deal's investment potential and bullish vs. bearish outlook

Buy the AMASS Botanics deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge